News

Read Story

Jaguar Animal Health, Inc. Announces Pricing of Initial Public Offering

May 13, 2015

San Francisco, CA : Jaguar Animal Health, Inc. (Nasdaq: JAGX), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today the pricing of its initial public offering of 2,860,000 shares of its common stock at a price to the public of $7.00 per share. All of the common stock is being offered by Jaguar Animal Health, Inc.

Read Story

Jaguar Animal Health Files Two Provisional Patent Applications, Deepening its Pipeline of Proprietary Gastrointestinal Products for Animals

March 4, 2015

San Francisco, CA : Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it recently filed two provisional patent applications with the United States Patent and Trademark Office involving crofelemer, an active pharmaceutical ingredient, and other anti-secretory products derived from the Croton lechleri tree. One application covers the novel use of a combination of such anti-secretory agents and the antimicrobial agent rifaximin to effectively treat symptoms associated with diarrhea of various causes in afflicted animals, and the second is for the beneficial prebiotic effect of the Croton lechleri-derived products in dairy calves and other animals.

Read Story

Jaguar Animal Health Signs Agreement with Latin America’s Largest Veterinary Biotechnology Company

Feb 26, 2015

San Francisco, CA : Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has entered into a supply and distribution agreement with Biogenesis Bagó, the largest veterinary biotechnology company in Latin America—a region that contains 370 million dairy and beef cattle and produces 11% of the world’s milk supply.

Read Story

Jaguar Animal Health Announces Outcome of Canine Proof-of-Concept Study for Canalevia

Feb 19, 2015

San Francisco, CA : Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products for companion and production animals, announced today significant top-line results of its recently completed, controlled, proof-of-concept study to evaluate the clinical benefits of Canalevia™, Jaguar’s lead prescription drug product candidate for the treatment of various forms of watery diarrhea in dogs.

Read Story

Jaguar Animal Health Files Ninth Investigational New Animal Drug Application

Feb 10, 2015

San Francisco, CA: Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products for companion and production animals, announced today that it has submitted an Investigational New Animal Drug application (“INAD”) with the Center for Veterinary Medicine (“CVM”) of the U.S. Food and Drug Administration for the treatment and prevention of recurrence of ulcers, and the treatment of diarrhea, in horses and foals. This is the ninth INAD Jaguar has filed.

Read Story

Jaguar Animal Health Signs Distribution Agreement with Vedco and Kicks off National Neonorm Calf Marketing Campaign

Feb 5, 2015

San Francisco, CA: Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it recently signed a multiyear distribution agreement with Vedco Inc., one of the largest national master distributors of veterinary products in the U.S., and has also kicked off a new marketing campaign for Neonorm™ Calf in advance of promoting the product at the World Ag Expo and the Western Veterinary Conference later this month.

Read Story

Jaguar Animal Health Initiates Filing of Its First New Animal Drug Application with FDA

Dec 22, 2014

San Francisco, CA : Canalevia™ is a New Prescription Drug Candidate for Treatment of Dogs Undergoing Chemotherapy. Jaguar Animal Health, Inc., an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has initiated the filing of the Company’s first New Animal Drug Application (NADA) with the U.S. Food and Drug Administration. The filing was submitted for Jaguar’s Canalevia prescription drug candidate, a proposed minor-use minor-species (MUMS) drug for use in dogs undergoing chemotherapy.

Read Story

Jaguar Animal Health Completes Equine Study for Safety & Palatability of Neonorm™ Foal Gastrointestinal Product

Dec 4, 2014

San Francisco, CA: Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has completed a study designed to gauge the safety and palatability of a species-specific formulation of the Company’s Neonorm gastrointestinal product in horse foals. Neonorm is Jaguar’s lead non-prescription product to improve gut health and normalize stool formation in animals suffering from watery diarrhea.

Read Story

Jaguar Animal Health Appoints Former Merial Executive to Head Regulatory Affairs

Nov 21, 2014

San Francisco, CA : Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, announced today that it has appointed Tim Dotson, a veteran animal health executive with more than 20 years of industry experience, as Executive Director, Regulatory Affairs.

Read Story

Jaguar Animal Health, Inc. Launches First Product, Neonorm™ Calf, at World Dairy Expo

Business Wire

Sep 29, 2014

Jaguar Animal Health, Inc. (“Jaguar”) announced the planned launch of its first commercial product, Neonorm™ Calf, at the upcoming World Dairy Expo in Madison, Wisconsin, September 30 – October 4, 2014. Neonorm™ Calf, a non-prescription product, is the latest advance in neonatal calf care that improves gut health by promoting normal stool care and rapidly reducing dehydration and the time to recovery

Read Story

Jaguar Animal Health, Inc. Files Eighth Investigational New Animal Drug Application

Business Wire

Sep 17, 2014

Jaguar Animal Health, Inc. (“Jaguar”), an animal health company focused on developing and commercializing first-in-class gastrointestinal and other proprietary health products for companion and production animals, announced today that it has submitted its eighth Investigational New Animal Drug application (“INAD”) with the Center for Veterinary Medicine (“CVM”) of the U.S. Food and Drug Administration for the treatment of insulin-resistance and metabolic syndrome in dogs.

Read Story

Jaguar Animal Health Names VP, Commercial Operations

Business Wire

July 8, 2014

Jaguar Animal Health, Inc. (“Jaguar” or the “Company”), an animal health company focused on developing and commercializing first-in-class gastrointestinal products for companion and production animals, today named Ian Parker, a seasoned executive who has spent 30 years in the animal health industry, Vice President, Commercial Operations.

Read Story

Jaguar Files INADAs for Diarrhea in Companion Animals and Horses

Business Wire

March 03, 2014

Jaguar Animal Health, Inc. (“Jaguar”) announced today that it has submitted three Investigational New Animal Drug Applications (“INADA”) with the Center for Veterinary Medicine of the US Food and Drug Administration (“CVM/FDA”) for SP-303 for use in dogs, cats and horses...

Read Story

Jaguar Announces Initial Close of Series A Round

PR Newswire

Feb 05, 2014

Jaguar Animal Health, Inc. (``Jaguar``) announced an initial $2 million closing of its Series A round of financing. BioVeda China Fund (``BVCF``), a private equity and growth capital investor based in China, funded the initial closing and will invest another $3 million by the end of...

Read Story

Drug Application For Chemo-induced Diarrhea In Dogs Moving Forward: PR Newswire

PR Newswire

Jan 14, 2014

An investigational new animal drug application (INADA) number has been received by Napo Pharmaceuticals, Inc. for its lead animal drug candidate, SP-303, which is isolated and purified from Croton lechleri, a medicinal plant sustainably harvested from the rain forest. The target indication is chemotherapy-induced diarrhea (“CID”) in dogs.